A Trial to Evaluate the Efficacy and Safety of PQ912 in Patients With Early AD

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Alzheimer Disease

In brief

This is a Phase 2A multi-center, randomized, double blind, placebo-controlled, parallel group study of varoglutamstat, with a stage gate to Phase 2B. In Phase 2A there will be adaptive dosing evaluation of three dose levels with exposure to varoglutamstat or placebo for a minimum of 24 weeks, with preliminary evaluation of both cognitive function and pharmacodynamic changes on EEG spectral analysis in approximately 180 participants. In the event that the stage gate for Phase 2B is reached, then Phase 2B will assesses efficacy and longer-term safety in a larger study group, i.e., 414.

Key facts

Study ID
NCT03919162
Run by
Vivoryon Therapeutics N.V.
People needed
112
Starts
2021-11-15
Expected to finish
2024-08-12
Last updated by the study team
2025-12-12

Who can join

Age: 50 and older, up to 89. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.